Table 2 Micronucleus tests with SET-M33L peptide in human lymphocytes.

From: In vitro and in vivo efficacy, toxicity, bio-distribution and resistance selection of a novel antibacterial drug candidate

Compound/concentration (μg/ml)

Mean of binucleate cells containing micronuclei per 1000 cells

3h − S9

3h + S9

20h − S9

vehicle (control)

6.3

6.3

9.5

SET-M33L/7.5

6.0

4.0

8.5

SET-M33L/150

6.0

NA

NA

SET-M33L/300

NA

5.5

8.5

SET-M33L/350

7.0

NA

NA

SET-M33L/400

NA

6.0

9.5

MMC/0.2

28.0

NA

NA

MMC/0.05

NA

NA

22.5

COL/0.06

20.5

NA

NA

COL/0.01

NA

NA

19.0

CPA/10

NA

17.0

NA

  1. The table reports the mean of binucleated cells containing micronuclei after incubation with SET-M33L or positive controls at different concentrations. Lymphocytes, stimulated to divide by addition of PHA 48 hours prior to treatment, were exposed to SET-M33L for 3 hours (h) with and without exogenous metabolic activation (S9 mix), and for 20 hours (h) without S9 mix.
  2. MMC: Mitomycin C; COL: Colchicine; CPA: Cyclophosphamide; NA: culture not analysed for micronucleus frequency.